Epicrispr, Infinimmune snag combined $165M in VC cash

By /

Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.

Scroll to Top